Introduction: Sepsis is a prevalent illness that requires quick diagnosis and treatment due to its high death and morbidity rates. Soluble CD14 subtype (sCD14-ST), Presepsin appears to be an accurate biomarker in diagnosing neonatal sepsis patients. Material and Methods: One aerobic BacT/ALERT bottle was inoculated with collected blood samples, and the bottle was then incubated at 35°C for five days, or until microbial growth was observed. The semi-quantitative latex agglutination test revealed the presence of CRP. For measuring procalcitonin, the PCT sandwich ELISA assay was utilised. A human ELISA kit was used to measure the amount of presepsin. Results: Out of the 356 newborns admitted, 102 neonates in total were included in our study.There were 34 female infants and 68 male neonates. 45 newborns were full term, whilst 57 were preterm. With 16.12% of cases each, Staphylococcus aureus and Escherichia coli were the most prevalent.The symptoms that patients reported, fever accounting for 50% of cases and being the most common symptom. Presepsin was 1682±765.3 pg/ml, procalcitonin was 10.98±4.67 ng/ml, and C-reactive protein (CRP) was 21.58±15.60 mg/ml. Neonates had considerably greater presepsin levels, ranging from 85% to 96%. Conclusion: Presepsin may prove helpful in the future for identifying neonatal sepsis when combined with other test indicators.